Keyphrases
Heart Failure
59%
Heart Failure with Preserved Ejection Fraction (HFpEF)
51%
Patients with Heart Failure
34%
Type 2 Diabetes Mellitus (T2DM)
33%
Coronary Artery Disease
31%
Confidence Interval
25%
Hazard Ratio
21%
Meta-analysis
20%
Chronic Heart Failure
19%
Atrial Fibrillation
18%
Beta-blockers
17%
Loop Diuretics
17%
Type 2 Diabetic Patients
17%
Non-invasive Imaging
17%
Placebo
16%
Metformin
16%
Renal Effects
16%
Cardiovascular Effects
16%
Systematic Meta-analysis
16%
Heart Failure Treatment
16%
Up-titration
16%
Sinus Rhythm
16%
Cardiovascular Magnetic Resonance
14%
Scotland
14%
Empagliflozin
12%
Randomized Controlled Trial
12%
Major Adverse Cardiovascular Events
12%
Cardiovascular Risk
11%
Prognostic Significance
10%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
10%
Tailored Treatment
10%
Biology Study
10%
Novel Therapeutic Targets
10%
Angiotensin-converting Enzyme Inhibitor (ACEi)
9%
Cardiovascular Outcomes
9%
Left Ventricular Hypertrophy
9%
Subsequent Events
9%
New-onset Heart Failure
9%
Disease-associated
9%
Event Risk
9%
Heart Failure Patients
9%
Angiotensin Receptor Blockers
8%
Failure Study
8%
Disease Progression
8%
Echocardiography
8%
Coronary Heart Disease Events
8%
Aortic Valve Stenosis
8%
Diabetic Cardiomyopathy
8%
Metabolic Modulation
8%
CV Events
8%
Pooled Cohort Equations
8%
Without Diabetes
8%
Epicardial Adipose Tissue
8%
Arterial Inflammation
8%
Patients with Diabetes
8%
Chromosome 9p21
8%
Cardiac Imaging Test
8%
Noninvasive Cardiac Imaging
8%
Individual Participant Data
8%
Left Ventricular Remodeling
8%
Sodium-glucose Cotransporter
8%
Patients with Coronary Artery Disease
8%
Dapagliflozin
8%
Proteomic Approach
8%
Diabetic Patients
8%
Clinical Data
8%
Metformin Therapy
8%
Biomarker Profile
8%
Disease Pathogenesis
8%
Mendelian Randomization
8%
Healthy Controls
8%
Mitochondrial Dysfunction
8%
Desmosine
8%
Heart Rate
8%
Neutrophil-to-lymphocyte Ratio
8%
Preserved Ejection Fraction
8%
Patient-controlled
8%
Stable Coronary Artery Disease
8%
Patients with Cardiovascular Diseases
8%
Amino Acid Homeostasis
8%
Disease Potential
8%
Aneurysm Disease
8%
Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors
8%
Ruptured Abdominal Aortic Aneurysm (rAAA)
8%
P-glycoprotein (P-gp)
8%
Genome-wide Association
8%
Echocardiographic
8%
Plasma Proteomics
8%
Odds Ratio
8%
Arterial Stiffness
8%
Metabolic Traits
8%
Late Gadolinium Enhancement
8%
Genomic Data
8%
Hypertensive Patients
8%
Aortopathy
8%
Exercise-based Cardiac Rehabilitation
8%
Ventricular Arrhythmia
8%
Cardiac Rehabilitation
8%
Patients with Chronic Heart Failure
8%
Mendelian Randomization Analysis
8%
Iron Deficiency
8%
Clarithromycin
8%
Worsening Heart Failure
8%
Inpatient Setting
8%
Population Cohort Study
8%
Microvascular Disease
8%
Cotransporter
8%
9p21 Locus
8%
Dilated Cardiomyopathy
8%
Population-based Cohort Study
8%
Metabolic Risk Factors
8%
Marfan Syndrome
8%
Iron Therapy
8%
Insulin Resistance
7%
Extracellular Volume
7%
Relative Risk
6%
Tayside
6%
Metformin Treatment
5%
All-cause Mortality
5%
Risk Difference
5%
Risk Stratification
5%
Computed Tomography
5%
Myocardial Infarction
5%
Clinical Outcomes
5%
Sudden Cardiac Death
5%
Hospital Admission
5%
Medicine and Dentistry
Congestive Heart Failure
89%
Heart Failure with Reduced Ejection Fraction
36%
Maturity Onset Diabetes of the Young
28%
Heart Failure with Preserved Ejection Fraction
24%
Biological Marker
22%
Cardiovascular Disease
21%
Coronary Artery Disease
20%
Atrial Fibrillation
18%
Meta-Analysis
17%
Systematic Review
16%
Beta Adrenergic Receptor Blocking Agent
16%
Mendelian Randomization Analysis
16%
Patient with Type 2 Diabetes
16%
Sinus Rhythm
16%
Loop Diuretic Agent
16%
Cardiovascular Effect
16%
Cardiac Magnetic Resonance Imaging
15%
Cardiovascular System
13%
Empagliflozin
12%
Hazard Ratio
11%
Placebo
10%
Cardiovascular Risk
10%
Randomized Controlled Trial
9%
Adipose Tissue
9%
Ejection Fraction
8%
Cohort Analysis
8%
Diseases
8%
Diabetes
8%
ACE Inhibitor
8%
Arterial Stiffness
8%
Diabetic Cardiomyopathy
8%
Left Ventricular Hypertrophy
8%
Angiotensin Receptor Antagonist
8%
Cardiac Imaging
8%
Microangiopathy
8%
Sodium Glucose Cotransporter 2
8%
Subtilisin
8%
Glycon
8%
Iron Supplement
8%
Kexin
8%
Desmosine
8%
Heart Rehabilitation
8%
Abdominal Aortic Aneurysm
8%
Diabetes Mellitus
8%
Cotransporter
8%
Serine Proteinase
8%
Aortopathy
8%
Heart Ventricle Arrhythmia
8%
Dilated Cardiomyopathy
8%
Marfan Syndrome
8%
Lymphocyte
8%
Gadolinium
8%
Neutrophil
8%
Disease Exacerbation
8%
Proteomics
8%
Urinary System
7%
Insulin Resistance
7%
Photograph
6%
Odds Ratio
5%
Attributable Risk
5%
Risk Stratification
5%
Myocardial Infarction
5%
Echocardiography
5%
Computer Assisted Tomography
5%
Sudden Cardiac Death
5%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Heart Failure with Reduced Ejection Fraction
35%
Non Insulin Dependent Diabetes Mellitus
27%
Atrial Fibrillation
18%
Beta Adrenergic Receptor Blocking Agent
17%
Cardiovascular Risk
17%
Cohort Study
17%
Metformin
16%
Heart Failure with Preserved Ejection Fraction
16%
Placebo
15%
Cardiovascular Disease
13%
Biological Marker
12%
Coronary Artery Disease
11%
Randomized Controlled Trial
11%
Dipeptidyl Carboxypeptidase Inhibitor
9%
Loop Diuretic Agent
9%
Heart Left Ventricle Hypertrophy
8%
Angiotensin Receptor Antagonist
8%
Diseases
8%
Empagliflozin
8%
P-Glycoprotein
8%
Desmosine
8%
Disease Exacerbation
8%
Diabetic Cardiomyopathy
8%
Clarithromycin
8%
Serine Proteinase
8%
Abdominal Aortic Aneurysm
8%
Amino Acid
8%
Sodium Glucose Cotransporter 2
8%
Heart Ventricle Remodeling
8%
Dapagliflozin
8%
Subtilisin
8%
Kexin
8%
Microangiopathy
8%
Iron
8%
Heart Infarction
6%